Share this article on:

Safety and Efficacy of Micafungin in Extremely Low Birthweight Infants

Schüller, Simone S. MD1,2,3; Bauer, Carina1; Unterasinger, Lukas MSc1; Berger, Angelika MD1

The Pediatric Infectious Disease Journal: September 28, 2017 - Volume Publish Ahead of Print - Issue - p
doi: 10.1097/INF.0000000000001787
Brief Reports: PDF Only

Little is known about side effects of micafungin in extremely low birthweight (ELBW) infants. In a retrospective single center study 19 ELBW infants were analyzed for micafungin efficacy and safety. At a mean±SD daily dosage of 7.5 ± 2.0mg/kg no clinically relevant side effects were observed. A significant increase of liver enzymes was reversible after treatment.

1 Department of Pediatrics, Division of Neonatology, Pediatric Intensive Care Medicine and Neuropediatrics, Medical University of Vienna, Vienna, Austria

2 Precision Vaccines Program, Department of Medicine, Division of Infectious Diseases, Boston Children’s Hospital, Boston, Massachusetts, USA

3 Harvard Medical School, Boston, Massachusetts, USA

The authors have no conflicts of interest or funding to disclose.

Corresponding Author: Simone S. Schüller, MD, Department of Medicine, Division of Infectious Diseases, 300 Longwood Avenue, Boston, Massachusetts 02115, Phone: 617-919-2906 | Fax: 617-730-0254, simone.schueller@childrens.harvard.edu

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.